Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
复制标题
DOI：
10.1016/j.ijid.2021.11.009
复制
发表时间：
2022-01
期刊：
影响因子：
--
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Zheng C;Shao W;Chen X;Zhang B;Wang G;Zhang W
评估2019冠状病毒病（COVID-19）疫苗有效性（VE）与现实环境中的相关结果。纳入了2020年8月6日至2021年10月6日期间报告COVID-19 VE的研究。估计了针对COVID-19相关疾病的汇总VE（95%置信区间（95% CI））。结果以森林图表示。还进行了预定义的亚组分析和敏感性分析。本荟萃分析共纳入51条记录。在完全接种疫苗的人群中，（SARS-CoV-2）感染、COVID-19相关住院、入住重症监护室和死亡的发生率为89.1%（95% CI 85.6-92.6%）、97.2%（95% CI 96.1-98.3%）、97.4%（95% CI 96.0-98.8%）和99.0%（95% CI 98.5-99.6%）。≥16岁的一般人群、老年人和医护人员的抗感染VE分别为86.1%（95% CI 77.8-94.4%）、83.8%（95% CI 77.1-90.6%）和95.3%（95% CI 92.0-98.6%）。对于那些完全接种了抗感染疫苗的人，辉瑞BioNTech疫苗的有效性为91.2%，Moderna疫苗为98.1%，而CoronaVac疫苗的有效性为65.7%。COVID-19疫苗在现实环境中对SARS-CoV-2相关疾病具有高度保护作用。
To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6–92.6%), 97.2% (95% CI 96.1–98.3%), 97.4% (95% CI 96.0–98.8%), and 99.0% (95% CI 98.5–99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8–94.4%), 83.8% (95% CI 77.1–90.6%), and 95.3% (95% CI 92.0–98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%. The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings.
登录
查看更多内容
影响因子：
5.5
作者：
Patel MK;Bergeri I;Bresee JS;Cowling BJ;Crowcroft NS;Fahmy K;Hirve S;Kang G;Katz MA;Lanata CF;L'Azou Jackson M;Joshi S;Lipsitch M;Mwenda JM;Nogareda F;Orenstein WA;Ortiz JR;Pebody R;Schrag SJ;Smith PG;Srikantiah P;Subissi L;Valenciano M;Vaughn DW;Verani JR;Wilder-Smith A;Feikin DR
通讯作者：
Feikin DR
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
13.8
作者：
Chodick G;Tene L;Patalon T;Gazit S;Ben Tov A;Cohen D;Muhsen K
通讯作者：
Muhsen K
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
影响因子：
7.8
作者：
Gómez CE;Perdiguero B;Esteban M
通讯作者：
Esteban M